Mathieu Pecqueux

Dr. Mathieu Pecqueux

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NGNicole Ganig
Nicole Ganig
FBFranziska Baenke
Franziska Baenke
MTMay-Linn Thepkaysone
May-Linn Thepkaysone
KLKuailu Lin
Kuailu Lin
VRVenkatesh S. Rao
Venkatesh S. Rao
CKChristoph Kahlert
Christoph Kahlert
The treatment of colorectal cancer (CRC) has improved during the last decades, but methods for crucial early diagnosis are yet to be developed. The influence of the tumour microenvironment on liquid biopsies for early cancer diagnostics are gaining growing interest, especially with emphasis on exosomes (EXO), a subgroup of extracellular vesicles (EVs). In this study, we established paired cancer-associated (CAFs) and normal fibroblasts (NF) from 13 CRC patients and investigated activation status-related protein abundance in derived EXOs. Immunohistochemical staining of matched patient tissue was performed and an independent test cohort of CRC patient plasma-derived EXOs was assessed by ELISA. A total of 11 differentially abundant EV proteins were identified between NFs and CAFs. In plasma EXOs, the CAF-EXO enriched protein EDIL3 was elevated, while the NF-EXO enriched protein QSOX1 was diminished compared to whole plasma. Both markers were significantly reduced in patient-matched CRC tissue compared to healthy colon tissue. In an independent test cohort, a significantly reduced protein abundance of QSOX1 was observed in plasma EXOs from CRC patients compared to controls and diagnostic ROC curve analysis revealed an AUC of 0.904. In conclusion, EXO-associated QSOX1 is a promising novel marker for early diagnosis and non-invasive risk stratification in CRC.

1 September 2018 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
FTFreya Trautmann
Freya Trautmann
CRChristoph Reißfelder
Christoph Reißfelder
MPMathieu Pecqueux
Mathieu Pecqueux
JWJürgen Weitz
Jürgen Weitz
JSJochen Schmitt
Jochen Schmitt

6 May 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CKChristoph Kahlert
Christoph Kahlert
TLTristan Lerbs
Tristan Lerbs
MPMathieu Pecqueux
Mathieu Pecqueux
EHEsther Herpel
Esther Herpel
MHMichael Hoffmeister
Michael Hoffmeister
MKMoritz Koch
Moritz Koch
Epithelial‐to‐mesenchymal transition (EMT) contributes significantly to tumor progression and metastasis. The assessment of EMT‐associated transcription factors could be a promising approach to identify biomarkers and potential therapeutic targets in colorectal cancer. In our study, we focused on the transcription factor “Sine oculis homeobox” (SIX) 1, which is a member of the superfamily of the homeobox genes and has been described to promote EMT in different types of tumors. Immunohistochemistry against SIX1 was performed on colorectal mucosa, adenomas, carcinomas‐in situ and primary adenocarcinomas. An expression score was developed and subsequently assessed for its prognostic value in two independent cohorts. Cohort 1 consisted of 128 patients with stage I–III colorectal cancer; cohort 2 included 817 patients with stage I–III colorectal cancer who had participated in the DACHS study. HCT‐116 cells were transfected with SIX1 plasmids and subjected to migration and colony formation assays. The expression of SIX1 increases gradually from mucosa to colorectal adenocarcinomas (p > 0.0001). Univariate and multivariate analyses reveal that high expression of SIX1 is associated with decreased overall survival (cohort 1: HR: 4.01, CI: 1.20–14.07, p = 0.025; cohort 2: HR: 1.43, CI: 1.014–2.02, p = 0.047). Overexpression of SIX1 induces a more mesenchymal‐like phenotype in HCT‐116 cells and enhances tumor migration. High expression of SIX1 is an independent prognostic marker in colorectal cancer. It might be a promising biomarker to stratify patients into different risk groups. Moreover, targeting SIX1 might be a novel therapeutic approach in patients with colorectal cancer.

5 October 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
MPMathieu Pecqueux
Mathieu Pecqueux
CRCarina Riediger
Carina Riediger
MDMarius Distler
Marius Distler
FOFlorian Oehme
Florian Oehme
UBUlrich Bork
Ulrich Bork
CKChristoph Kahlert
Christoph Kahlert
Purpose: Clinical abundance of artificial intelligence has increased significantly in the last decade. This survey aims to provide an overview of the current state of knowledge and acceptance of AI applications among surgeons in Germany.Methods: A total of 357 surgeons from German university hospitals, academic teaching hospitals and private practices were contacted by e-mail and asked to participate in the anonymous survey.Results: A total of 147 physicians completed the survey. The majority of respondents (n = 85, 52.8%) stated that they were familiar with AI applications in medicine. Personal knowledge was self-rated as average (n = 67, 41.6%) or rudimentary (n = 60, 37.3%) by the majority of participants. On the basis of various application scenarios, it became apparent that the respondents have different demands on AI applications in the area of “diagnosis confirmation” as compared to the area of “therapy decision.” For the latter category, the requirements in terms of the error level are significantly higher and more respondents view their application in medical practice rather critically. Accordingly, most of the participants hope that AI systems will primarily improve diagnosis confirmation, while they see their ethical and legal problems with regard to liability as the main obstacle to extensive clinical application.Conclusion: German surgeons are in principle positively disposed toward AI applications. However, many surgeons see a deficit in their own knowledge and in the implementation of AI applications in their own professional environment. Accordingly, medical education programs targeting both medical students and healthcare professionals should convey basic knowledge about the development and clinical implementation process of AI applications in different medical fields, including surgery.

10 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MPMathieu Pecqueux
Mathieu Pecqueux
JFJohannes Fritzmann
Johannes Fritzmann
MAMariam Adamu
Mariam Adamu
KTKristian Thorlund
Kristian Thorlund
CKChristoph Kahlert
Christoph Kahlert
NRNuh N Rahbari
Nuh N Rahbari
Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis

30 December 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
CKChristoph Kahlert
Christoph Kahlert
MFMaria Fiala
Maria Fiala
GMGabriel Musso
Gabriel Musso
NHNiels Halama
Niels Halama
SKSophia Keim
Sophia Keim
MKMoritz Koch
Moritz Koch
Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer